| News
Basel startup Nutrix beats 900 startups
11.11.2019
The Basel startup Nutrix has won a competition at the Web Summit with its business concept. It has developed a nanosensor that measures glucose levels in users’ saliva to prevent diabetes. Nutrix is supported by the Venture Mentoring program of BaselArea.swiss and has been shortlisted for the DayOne Accelerator.

Maria Hahn, Founder of Nutrix, on Center Stage of Web Summit 2019
According to an article at startupticker.ch, the Web Summit, one of the largest annual conferences for the global technology industry, took place in the first week of November. During the conference a competition for start-ups was also held, enabling them to present their business concept. This year, around 900 startups took part, and the winner was the Basel-based Medtech startup Nutrix.
It has developed a nanosensor that is placed on the tooth to measure glucose levels in users’ saliva and transfers information to an external app. At the same time, the sensor tracks food intake and provides dietary tips on this basis, allowing it to be used to prevent diabetes. Co-founder Maria Hahn underlined during the presentation that preventative measures such as these could shape the future of medicine.
Hahn and the second co-founder Nikjil Singh first developed their idea together in spring this year. They are already working towards building a prototype. Nutrix has close links with Basel Children’s Hospital (UKBB).
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More